



Figure S6: γ -H2AX immunostaining of *BRCA2* deficient CAPAN1 vs. wild-type *BRCA2* expressing BRCA2/CIN treated with 10 μ M olaparib +/- 10 ng/ml TRAIL or dimethyl sulfoxide (DMSO) control for 48 h.